Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer

• Status: Completed
• Trial end date: 2002-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients who have stage II or stage III prostate cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Collaborators: National Cancer Institute (NCI); Rhone-Poulenc Rorer
• Treatments: Docetaxel

Criteria

Eligibility Criteria:

• Histologically confirmed adenocarcinoma of the prostate

• Potential candidate for radical prostatectomy

• Any of the following:

• Clinical stage T3 patients

• Serum PSA at least 20 ng/mL

• Gleason score 8-10

• Clinical T2 disease and either of the following:

• MRI evidence of seminal vesicle involvement

• Gleason 4+3 cancer with either 5 or 6 biopsies positive

• CALGB 0-1

• WBC greater than 3,000/mm3

• Hematocrit greater than 30%

• Platelet count greater than 100,000/mm3

• SGOT, total bilirubin within normal limits

• Signed Informed consent

Exclusion Criteria:

• No prior hormones, radiation or chemotherapy for prostate cancer

• Evidence of serious active infection